Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.41 |
| ▸ | MGLL | Q99685 | 4/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 1/20 | 0.37 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007646 | 0.83 | PDK1 (0.51) | MGLLPTGDR2 | |
| SCHEMBL2007649 | 0.78 | CA1 (0.40) | — | |
| SCHEMBL28456817 | 0.76 | MGLL (0.40) | CCR1MGLLPTGDR2DRD2DRD3 | |
| SCHEMBL17941914 | 0.76 | MGLL (0.40) | CCR1MGLLPTGDR2DRD2DRD3 | |
| SCHEMBL14645770 | 0.75 | MGLL (0.56) | CCR1MGLLPTGDR2 | |
| SCHEMBL20788244 | 0.75 | CCR1 (0.47) | CCR1MGLLPTGDR2FPR3GPR65 | |
| SCHEMBL20788251 | 0.75 | CCR1 (0.47) | CCR1MGLLPTGDR2FPR3GPR65 | |
| SCHEMBL4047974 | 0.75 | FAAH (0.52) | CCR1MGLLPTGDR2DRD2DRD3 | |
| SCHEMBL5743699 | 0.73 | ALOX15 (0.39) | DRD2DRD3 | |
| SCHEMBL18011026 | 0.73 | ALOX15 (0.39) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960390-B1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LTD (GB) | 2010-07-21 | — | — | EP | disclosed |
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GLAXO GROUP LIMITED | 2008-12-11 | — | — | US | disclosed |
| EP-1960390-A1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007065669-A1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GPR88, GPR68, GPBAR1 | CCR1 1017/4885MGLL 398/4885PTGDR2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.